Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CNT047
MIFTS: 57

Contact Dermatitis

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Contact Dermatitis

About this section

MalaCards integrated aliases for Contact Dermatitis:

Name: Contact Dermatitis 12 74 15 17 71
Contact Dermatitis/eczema 12
Dermatitis, Venenata 12
Dermatitis Venenata 12
Dermatitis, Contact 43
Dermatitis Contact 54
Contact Eczema 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:2773
MeSH 43 D003877
NCIt 49 C26743
SNOMED-CT 67 40275004
UMLS 71 C0011616
Sources

Summaries for Contact Dermatitis

About this section
MalaCards based summary : Contact Dermatitis, also known as contact dermatitis/eczema, is related to 1-chloro-2,4-dinitrobenzene allergic contact dermatitis and nickel allergic contact dermatitis, and has symptoms including pruritus and exanthema. An important gene associated with Contact Dermatitis is IL31 (Interleukin 31), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Mineral oil and Glycerol have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Wikipedia : 74 Contact dermatitis is a type of inflammation of the... more...

Sources

Related Diseases for Contact Dermatitis

About this section

Diseases related to Contact Dermatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 873)
# Related Disease Score Top Affiliating Genes
1 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 34.9 IL4 IL2
2 nickel allergic contact dermatitis 34.4 SELE IL5 IL4 IL10 IFNG CD4
3 palladium allergic contact dermatitis 34.3 TNF IL1B IL17A IL10 CCL17
4 irritant dermatitis 33.6 TNF KRT16 IL6 IL4 IL31 IL1B
5 toxicodendron dermatitis 33.5 TNF SELE IL2 ICAM1 CXCL8
6 exanthem 32.4 TNF IL6 IL2 IL10 CXCL8 CD4
7 allergic contact dermatitis 32.3 TNF SELE IL6 IL5 IL4 IL31
8 pustulosis of palm and sole 31.7 TNF IL17A CXCL8
9 ige responsiveness, atopic 31.7 IL5 IL4 IL10 IFNG
10 urticaria 31.5 TNF SELE IL6 IL5 IL4 IL31
11 rosacea 31.3 TNF IL6 CXCL8
12 alopecia 31.2 TNF IL4 IL2 IFNG
13 neurofibromatosis, type ii 31.1 TNF IL6 IL1A CXCL8
14 seborrheic dermatitis 31.0 TNF FLG CXCL8 CD4
15 discoid lupus erythematosus 31.0 KRT16 IL10 FLG
16 latex allergy 30.9 TNF IL5 IL4 IFNG FLG
17 metal allergy 30.9 IL4 IL17A IL10 CD4
18 oral lichen planus 30.9 IL1A ICAM1 CXCR3
19 purpura 30.8 TNF IL6 IL4 IL10
20 acute generalized exanthematous pustulosis 30.7 IL17A CXCL8
21 pulpitis 30.7 TNF IL6 IL1B IL1A CXCL8
22 folliculitis 30.7 IL5 IL4 IFNG CD4
23 mite infestation 30.6 IL5 FLG CD4
24 vasculitis 30.6 TNF SELE IL6 IL17A ICAM1
25 bullous pemphigoid 30.6 IL5 IL4 IL31 CXCL8 CCL17
26 mycosis fungoides 30.5 IL5 IL2 IFNG CXCR3 CCL17
27 blepharoconjunctivitis 30.5 IL4 CXCL8 CD4
28 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.5 IL17A IL10 IFNG
29 dermatitis, atopic, 8 30.5 IL1B IL10 CXCL8
30 stevens-johnson syndrome/toxic epidermal necrolysis 30.5 IL5 IL2 IFNG CXCR3 CCL17
31 corticosteroid allergy 30.5 IL5 IL4 IFNG FLG CD4
32 erysipelas 30.5 TNF IL6 IL2
33 scabies 30.5 IL5 IL1A IL10 FLG CXCL8 CD4
34 dermatitis 30.5 TNF KRT16 IL6 IL5 IL4 IL31
35 herpes zoster 30.4 TNF IL2 IL10 IFNG CD4
36 milk allergy 30.4 TNF IL5 IL4 IL10
37 fixed drug eruption 30.3 IL2 IFNG
38 arthropathy 30.3 TNF IL6 IL1B IFNG
39 actinic prurigo 30.3 TNF SELE IL1B ICAM1
40 septic arthritis 30.3 IFNG CXCR3 CXCL8
41 laryngitis 30.3 TNF IL6 IL1B IL1A
42 irritable bowel syndrome 30.3 TNF IL6 IL10 CXCL8
43 cellulitis 30.3 TNF IL6 IL5 IL10 CD4
44 pulmonary fibrosis 30.3 IL1B CXCR3 CXCL8 CCL17
45 varicose veins 30.2 TNF IL6 ICAM1 CXCL8
46 cutaneous t cell lymphoma 30.2 IL5 IL4 IL2 IFNG CXCR3 CCL17
47 pertussis 30.2 TNF IL6 IL1B IL1A IL10 CXCL8
48 blepharitis 30.2 TNF IL6 IL4 CXCL8 CD4
49 urethritis 30.2 TNF IL6 CXCL8 CD4
50 idiopathic interstitial pneumonia 30.2 IL4 IFNG ICAM1 CXCL8

Graphical network of the top 20 diseases related to Contact Dermatitis:



Diseases related to Contact Dermatitis
Sources

Symptoms & Phenotypes for Contact Dermatitis

About this section

UMLS symptoms related to Contact Dermatitis:


pruritus, exanthema

GenomeRNAi Phenotypes related to Contact Dermatitis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.83 CXCL8 ICAM1 IL10 IL17A IL1A IL1B
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.83 CXCL8 ICAM1 IL10 IL17A IL1A IL1B

MGI Mouse Phenotypes related to Contact Dermatitis:

45 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.31 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
2 cellular MP:0005384 10.29 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
3 homeostasis/metabolism MP:0005376 10.28 CD4 CXCR3 ICAM1 IFNG IL10 IL17A
4 growth/size/body region MP:0005378 10.27 CD4 ICAM1 IFNG IL10 IL17A IL1B
5 immune system MP:0005387 10.24 CCL17 CD4 CXCR3 ICAM1 IFNG IL10
6 cardiovascular system MP:0005385 10.22 CXCR3 ICAM1 IFNG IL10 IL1A IL1B
7 digestive/alimentary MP:0005381 10.22 CD4 ICAM1 IFNG IL10 IL17A IL2
8 integument MP:0010771 10.1 CD4 ICAM1 IFNG IL10 IL17A IL1A
9 craniofacial MP:0005382 10.04 IFNG IL10 IL17A IL1B IL4 KRT16
10 liver/biliary system MP:0005370 9.86 IFNG IL10 IL2 IL4 IL5 IL6
11 neoplasm MP:0002006 9.85 CXCR3 ICAM1 IFNG IL10 IL1A IL1B
12 no phenotypic analysis MP:0003012 9.5 CD4 IFNG IL10 IL17A IL2 IL4
13 respiratory system MP:0005388 9.32 CXCR3 IFNG IL10 IL17A IL2 IL4
Sources

Drugs & Therapeutics for Contact Dermatitis

About this section

Drugs for Contact Dermatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
2
Glycerol Approved, Investigational Phase 4 56-81-5 753
3
Petrolatum Approved, Investigational Phase 4 8009-03-8
4
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
5
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
6
Apremilast Approved, Investigational Phase 4 608141-41-9 11561674
7 Dermatologic Agents Phase 4
8 Emollients Phase 4
9 Cyclooxygenase Inhibitors Phase 4
10 Disinfectants Phase 4
11 Sodium hypochlorite Phase 4
12 Eusol Phase 4
13 Antibodies, Monoclonal Phase 4
14 Antibodies Phase 4
15 Immunoglobulins Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Bacterial Agents Phase 4
18 Angiogenesis Inhibitors Phase 4
19
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
20
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
21
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
22 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
23
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
24
Silver sulfadiazine Approved, Vet_approved Phase 3 22199-08-2 441244
25
Sulfadiazine Approved, Investigational, Vet_approved Phase 3 68-35-9 5215
26
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
27
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
28
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
29
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
30
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
31
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
32
Gemcitabine Approved Phase 3 95058-81-4 60750
33 Coconut Approved Phase 3
34
Calcifediol Approved, Nutraceutical Phase 3 19356-17-3 6433735 5283731
35
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
36
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
37
Vitamin D3 Approved, Nutraceutical Phase 3 67-97-0 6221 5280795
38
Ergocalciferol Approved, Nutraceutical Phase 3 50-14-6 5280793
39
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
40 Methylprednisolone Acetate Phase 3
41 Neuroprotective Agents Phase 3
42 Antitubercular Agents Phase 3
43 Chelating Agents Phase 3
44 Antidotes Phase 3
45 Antiparasitic Agents Phase 3
46 Antiprotozoal Agents Phase 3
47 Hydroxycholecalciferols Phase 3
48 Anti-Infective Agents, Local Phase 3
49 Antiemetics Phase 3
50 Gastrointestinal Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 108)
# Name Status NCT ID Phase Drugs
1 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
2 An Open Single Centre Evaluation of the Reactivity of the T.R.U.E. Test Quaternium-15 Patch and a Real Use Exposure in Subjects Known to Be Allergic to Quaternium-15 Unknown status NCT00311454 Phase 4 T.R.U.E.Test
3 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
4 A Randomized, Double-Blind, Vehicle-Controlled, Multicenter Trial to Assess the Safety and Efficacy of 0.1% Tacrolimus Ointment in the Treatment of Chronic Allergic Contact Dermatitis Completed NCT00667056 Phase 4 tacrolimus ointment;placebo ointment
5 Clinical Evaluation of TRUE Test Ethylenediamine Dihydrochloride Allergen: Bioequivalence of Vehicle Formulations Completed NCT01798589 Phase 4 Ethylenediamine dihydrochloride
6 Clinical Evaluation of T.R.U.E. TEST® Panel 1.1, 2.1 and 3.1: in Children and Adolescents Completed NCT00795951 Phase 4
7 Evaluation of Provase in the Post Burn Rehabilitation Population for Itch Control and Moisturization Properties Completed NCT00782054 Phase 4
8 A Comparative Evaluation of Diclofenac Sodium Transdermal Patch, Oral Diclofenac Sodium With Intramuscular Injections of Diclofenac Sodium in Patients Suffering From Oral Pain: A Randomized Control Trial Completed NCT03221946 Phase 4 Diclofenac Sodium;Diclofenac sodium;Diclofenac
9 The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis Completed NCT00179959 Phase 4 Sodium hypochlorite (bleach) baths;Mupirocin ointment;Water;Petrolatum Ointment
10 The Effects of Dupilumab on Allergic Contact Dermatitis Not yet recruiting NCT03935971 Phase 4 Dupilumab
11 An Open-label, Single-Arm Pilot Study Investigating the Efficacy and Safety of Apremilast for the Treatment of Moderate to Severe Chronic Hand Dermatitis Terminated NCT03741933 Phase 4 Apremilast 30mg
12 Comparative Evaluation of the Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in the Treatment of Pediatric and Adult Dermatosis Unknown status NCT01011621 Phase 3 0.5% prednisolone acetate cream;0.1% betamethasone valerate cream
13 Anti-IL-17 a New Treatment for Contact Dermatititis Unknown status NCT02778711 Phase 3 secukinumab
14 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Gold Sodium Thiosulfate, Hydrocortisone-17-Butyrate, Methyldibromoglutaronitrile, Bacitracin, Parthenolide, Disperse Blue 106, and Bronopol Completed NCT00640614 Phase 3
15 A Randomized Controlled Clinical Trial Comparing The Efficacy and Safety of Open Dressing With Petrolatum Jelly vs. Standard Gauze Dressing With Silver Sulfadiazine in the Treatment of Filipino Adults Aged 18-45 Years Old With Superficial Partial Thickness Burns Less Than or Equal to 10% Total Surface Area Who Are Seen at the Philippine General Hospital Burn Outpatient Clinic Completed NCT02109718 Phase 3 Open Dressings with Petrolatum Jelly;Silver Sulfadiazine Gauze Dressing Group
16 Bio-equivalency Study of the Effects of Vitamin D2 and Vitamin D3 Supplements on 25-hydroxyvitamin D Levels in Exclusively Breast Fed Canadian Infants Completed NCT01190137 Phase 3
17 Phase 3 Study, Randomized, Double-blind, Parallel to Evaluate Ketoconazole and Betamethasone Dipropionate(Candicort®) Compared to Clotrimazole and Dexamethasone Acetate(Baycuten N®) in Relief of Fungal Infections/Dermatophytosis Symptoms. Recruiting NCT02582177 Phase 3 Candicort®;Nizoral®;Baycuten N®;Canesten®
18 LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure Recruiting NCT02973789 Phase 3 Immune checkpoint inhibitors or docetaxel
19 Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma Recruiting NCT03377491 Phase 3 Gemcitabine;nab paclitaxel
20 Vitamin D3 Supplementation in Polymorphic Light Eruption: Randomized Double-blinded Placebo-controlled Trial Terminated NCT01595893 Phase 3 Oral Vitamin D 3;Miglyol 812 N
21 Clinical Evaluation of T.R.U.E. TEST Panel 3.2 in Children and Adolescents Withdrawn NCT01518348 Phase 3
22 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study Unknown status NCT02028208 Phase 2
23 An Efficacy and Safety Pilot Study Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Treatment of AGA Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
24 Phase 2 Randomized, Multicenter, Safety and Efficacy Trial to Evaluate Different Oral Benznidazole Monotherapy and Benznidazole/E1224 Combination Regimens for the Treatment of Adult Patients With Chronic Indeterminate Chagas Disease Unknown status NCT03378661 Phase 2 Benznidazole;E1224;E1224 Placebo;Benznidazole Placebo
25 A Double-blind, Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of Three Weeks of Daily Dermal Application of MRX-6 (2% HyPE) on the Treatment of Mild to Moderate Contact Dermatitis of the Hand and Forearm Completed NCT00867607 Phase 1, Phase 2 MRX-6;Steroid
26 A Phase 2, Open-label, Investigator-Initiated Study to Evaluate the Safety and Efficacy of Apremilast in Subjects With Recalcitrant Contact or Atopic Dermatitis Completed NCT00931242 Phase 2 Apremilast
27 Clinical Evaluation of T.R.U.E. TEST® Fragrance Mix and Thimerosal Allergens: Bioequivalence of Polyvinylpyrrolidone (PVP) Formulations Completed NCT00612768 Phase 2
28 Clinical Evaluation of Hydroxyisohexyl 3-cyclohexene Carboxaldehyde (Lyral®) Dose Response Study Completed NCT02028182 Phase 2
29 Clinical Evaluation of Bacitracin. A Phase II Dose-Response Study Completed NCT00132600 Phase 2 bacitracin (allergen)
30 Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate for ”TRUE Test® Panel 3” – a Phase II, Dose-Response Study. Completed NCT00133341 Phase 2 Goldnatriomthiosulphate, MDBGN, parthenolide
31 Clinical Evaluation of T.R.U.E. TEST® Panel 3.2 Allergens: Bronopol and Disperse Blue 106 Dose Response Study Completed NCT00640250 Phase 2
32 A Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Center Study of the Intradermal Injection of rHuPH20 or Placebo in Subjects With Nickel Allergic Contact Dermatitis Completed NCT00928447 Phase 2 rHuPH20;Placebo
33 Novel Protective Underglove Completed NCT00170586 Phase 2
34 A Randomized, Double-Blind, Vehicle-Controlled, Sample Size Adaptive Design Study to Evaluate the Safety and Efficacy of Topically Applied EB01 Cream in Healthy Adult Volunteers and Adult Subjects With Chronic Allergic Contact Dermatitis Recruiting NCT03680131 Phase 2 EB01 Cream Placebo;EB01 Cream 0.2%;EB01 Cream 1.0%;EB01 Cream 2.0%
35 Valchlor Therapy in Conjunction With Triamcinolone 0.1% Ointment for the Treatment of Contact Dermatitis in Patients With Early Stage Cutaneous T-cell Lymphoma (Mechlorethamine Induced Dermatitis Avoidance Study) Recruiting NCT03380026 Phase 2 Triamcinolone;Valchlor 0.016 % Topical Gel
36 Clinical Evaluation of Metal Panel Allergens: Aluminum, Copper, Manganese, Molybdenum, Tin, Titanium, Vanadium and Zinc Dose Response Study Recruiting NCT02615249 Phase 2
37 HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Sorafenib For Advanced Hepatocellular Carcinoma (HCC) Recruiting NCT03606590 Phase 2 Sorafenib
38 Clinical Treatment of Alopecia Areata With Stem Cell Educator Therapy and Oral Minoxidil Not yet recruiting NCT04011748 Phase 2
39 Validation of a Novel Composite of Skin Biomarkers as a Primary Outcome Measure for Evaluating the Safety of Treatments for Atopic Dermatitis: a Randomized Controlled Trial (Phase 2) Comparing the Effects of Crisaborole 2% Ointment to Betamethasone Valerate 0.1% Cream on Skin Structure and Function in Participants With Atopic Dermatitis. Not yet recruiting NCT04194814 Phase 2 crisaborole (2%) ointment;betamethasone valerate 0.1% cream
40 A Proof-of-Principle Study Investigating the Effect of Single Doses of NI-0801 on Nickel Induced Contact Dermatitis Completed NCT01244607 Phase 1 Placebo;NI-0801
41 Pilot, Phase I, Single Blind Trial to Assess Itch Behavior in Nickel Sulphate Sensitized Volunteers. (PRURITUS- Nimpa Study). Completed NCT01529320 Phase 1 Adventan® (methylprednisolone aceponate 0,1%)
42 Phase 1 Study to Demonstrate Efficacy of Epikeia Coatings in a Human Clinical Trial Completed NCT00614289 Phase 1
43 A Randomized, Controlled Study to Evaluate the Effect of Topically Applied BBI-2000 (5%) on Allergic Responses in Subjects With Contact Hypersensitivity to Diphencyprone Completed NCT03089775 Phase 1 BBI-2000;Vehicle
44 A Phase I, Single-Center, Double-Blind, Randomized, Single Ascending Dose Study of PDC-APB in Healthy Volunteers Completed NCT02700373 Phase 1 PDC-APB;Placebo
45 A Single-Site Study To Evaluate the Sensitization Potential of Topically Applied ATx201 in Healthy Human Volunteers Completed NCT03375957 Phase 1 ATx201;ATx201 Placebo Gel
46 A Phase I Study of the Immune Response to Herpes Simplex Virus Type 1 (HSV-1) and General Immune Health in Subjects Infected With HSV-1 Completed NCT03661541 Phase 1 Squaric Acid Dibutyl Ester
47 Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation Unknown status NCT00445029
48 Nickel Desensitization Using Topical Therapy Unknown status NCT01413477 Calcipotriol, Betamethasone, Calcipotriol & Betamethasone
49 Bariederm Cream in Chronic Contact Dermatitis Unknown status NCT02026700
50 Chemokine Expression in Nummular Dermatitis and Atopic Dermatitis Unknown status NCT01311986

Search NIH Clinical Center for Contact Dermatitis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


pramoxine
Pramoxine hydrochloride

Cochrane evidence based reviews: dermatitis, contact

Sources

Genetic Tests for Contact Dermatitis

About this section
Sources

Anatomical Context for Contact Dermatitis

About this section

MalaCards organs/tissues related to Contact Dermatitis:

40
Skin, Testes, T Cells, Lymph Node, Eye, Monocytes, Liver
Sources

Publications for Contact Dermatitis

About this section

Articles related to Contact Dermatitis:

(show top 50) (show all 13083)
# Title Authors PMID Year
1
Filaggrin mutations may confer susceptibility to chronic hand eczema characterized by combined allergic and irritant contact dermatitis. 54 61
19538184 2009
2
Protein contact dermatitis: allergens, pathogenesis, and management. 54 61
18845114 2008
3
Loss-of-function polymorphisms in the filaggrin gene are associated with an increased susceptibility to chronic irritant contact dermatitis: a case-control study. 54 61
18637008 2008
4
Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. 54 61
18416755 2008
5
Allergies in India: an analysis of 3389 patients attending an allergy clinic in Mumbai, India. 54 61
18828339 2008
6
Allergic contact dermatitis from natural rubber latex in atopic dermatitis and the risk of later Type I allergy. 54 61
15982232 2005
7
Establishment of an atopic dermatitis-like skin model in a hairless mouse by repeated elicitation of contact hypersensitivity that enables to conduct functional analyses of the stratum corneum with various non-invasive biophysical instruments. 54 61
15059180 2004
8
Expression of CS-1 fibronectin precedes monocyte chemoattractant protein-1 production during elicitation of allergic contact dermatitis. 54 61
12911787 2003
9
Nickel-induced cytokine production from mononuclear cells in nickel-sensitive individuals and controls. Cytokine profiles in nickel-sensitive individuals with nickel allergy-related hand eczema before and after nickel challenge. 54 61
10929769 2000
10
Ultraviolet-B exposure of human skin induces cytochromes P450 1A1 and 1B1. 54 61
10651994 2000
11
The CXCR3 activating chemokines IP-10, Mig, and IP-9 are expressed in allergic but not in irritant patch test reactions. 54 61
10504443 1999
12
Chromium induced contact dermatitis and indices for diagnosis. 54 61
17219860 1999
13
Keratin 17 is expressed during the course of SLS-induced irritant contact dermatitis, but unlike keratin 16, the degree of expression is unrelated to the density of dividing keratinocytes. 54 61
9686973 1998
14
In vivo cytokine profiles in allergic and irritant contact dermatitis. 54 61
8654078 1995
15
Cell-bound IgE and increased expression of Fc epsilon-receptors on dendritic cells in cutaneous infiltrates of mycosis fungoides. 54 61
1834378 1991
16
Mechanistic understanding of dendritic cell activation in skin sensitization: additional evidences to support potency classification. 61
31958493 2020
17
A Comprehensive Artificial Sweat Study for Quantitation of Nickel and Other Inorganic Elements Released from Imitation Earrings Purchased in Istanbul Market. 61
31940117 2020
18
Simulative structure and binding sites of lyral with olfactory receptor 10J5 using computational prediction methods. 61
32019422 2020
19
Isothiazolinones in cleaning products: Analysis with liquid chromatography tandem mass spectrometry of samples from sensitized patients and market. 61
31657463 2020
20
Allergic contact dermatitis caused by a black rubber handbrake handle. 61
31566764 2020
21
Contact dermatitis caused by glucose sensors in diabetic children. 61
31657469 2020
22
Skin bioengineering in the diagnosis of occupational protein contact dermatitis. 61
32009172 2020
23
Anti-inflammatory effect of lanoconazole on 12-O-tetradecanoylphorbol-13-acetate- and 2,4,6-trinitrophenyl chloride-induced skin inflammation in mice. 61
31724251 2020
24
12-year data on dermatologic cases in the Finnish Register of Occupational Diseases I: Distribution of different diagnoses and main causes of allergic contact dermatitis. 61
32037572 2020
25
Airborne allergic contact dermatitis due to acemetacin. 61
31617597 2020
26
Airborne allergic contact dermatitis caused by artichoke. 61
32017132 2020
27
Contact allergy to isothiazolinones epidemic: Current situation. 61
31515812 2020
28
Immune-competent in vitro co-culture models as an approach for skin sensitisation assessment. 61
31648045 2020
29
Proteomic analysis of haptenation by skin sensitisers: Diphencyprone and ethyl acrylate. 61
31669365 2020
30
Skin barrier damage after exposure to paraphenylenediamine. 61
31783056 2020
31
The epidemic of methylisothiazolinone contact allergy in Europe: follow-up on changing exposures. 61
31419348 2020
32
The implanted glucose monitoring system Eversense: An alternative for diabetes patients with isobornyl acrylate allergy. 61
31463958 2020
33
Determining the role of allergic contact dermatitis in mycosis fungoides. 61
32009234 2020
34
Vacuum-Assisted Closure for the Treatment of Deep Sternal Wound Infection After Pediatric Cardiac Surgery. 61
31568260 2020
35
Paeoniflorin inhibits MRGPRX2-mediated pseudo-allergic reaction via calcium signaling pathway. 61
31667930 2020
36
Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. 61
31820485 2020
37
Spinal GRPR and NPRA contribute to chronic itch in a murine model of allergic contact dermatitis. 61
32032577 2020
38
Bullous allergic contact dermatitis from disperse dyes in Lycra cycling shorts. 61
31566755 2020
39
Allergic contact dermatitis to decyl glucoside: Still an important allergen in Tinosorb M. 61
31566773 2020
40
Allergic contact dermatitis caused by tetrahydrofurfuryl acrylate in the adhesive of clip-on earrings. 61
31599966 2020
41
Allergic reactions to tattoos: Retrospective analysis of North American Contact Dermatitis Group data, 2001-2016. 61
31604096 2020
42
Allergic contact dermatitis due to neem oil: A case report and mini-review. 61
31823408 2020
43
Preventing relapses of airborne allergic contact dermatitis to isothiazolinones in wall paint by painting over with an isothiazolinone-free paint. 61
31587304 2020
44
Severe irritant reaction following sequential waxing and use of a chemical depilatory cream in an adolescent. 61
31769049 2020
45
Allergic contact dermatitis to triclosan-coated suture material. 61
31951289 2020
46
The value of pantomiming for allergic contact dermatitis. 61
31962091 2020
47
Photopatch Testing Among Members of the American Contact Dermatitis Society. 61
31905187 2020
48
Allergic contact dermatitis caused by the elastic borders of diapers. 61
31566747 2020
49
Photoallergic contact dermatitis due to benzophenone contained in swimming goggles. 61
31418871 2020
50
Acrylate allergic contact dermatitis caused by hair prosthesis fixative. 61
31423595 2020
Sources

Variations for Contact Dermatitis

About this section
Sources

Expression for Contact Dermatitis

About this section
Search GEO for disease gene expression data for Contact Dermatitis.
Sources

Pathways for Contact Dermatitis

About this section

Pathways related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 95)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 65
Show member pathways
 14.16 TNF IL6 IL5 IL4 IL31 IL2
2
ERK Signaling 63
Show member pathways
 13.98 TNF IL6 IL5 IL4 IL2 IL1B
3
PEDF Induced Signaling 63
Show member pathways
 13.85 TNF IL6 IL5 IL4 IL31 IL2
4
TGF-Beta Pathway 63
Show member pathways
 13.73 TNF IL6 IL5 IL4 IL2 IL1B
5
Akt Signaling 63
Show member pathways
 13.62 TNF IL6 IL5 IL4 IL2 IL1B
6
Cytokine Signaling in Immune system 65
Show member pathways
 13.55 TNF IL6 IL5 IL4 IL31 IL2
7
PAK Pathway 63
Show member pathways
 13.49 TNF IL6 IL5 IL4 IL2 IL1B
8
Toll-like Receptor Signaling Pathway 1 36
Show member pathways
 13.23 TNF IL6 IL2 IL1B IL10 IFNG
9
Human cytomegalovirus infection 36
Show member pathways
 13.03 TNF IL6 IL1B ICAM1 CXCL8 CD4
10
Measles 36
Show member pathways
 13 TNF IL6 IL2 IL1B IL1A IFNG
11
Pathways in cancer 36
12.95 IL6 IL5 IL4 IL2 IFNG CXCL8
12
RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways 65
Show member pathways
 12.84 TNF IL6 IL1B IFNG CXCL8
13
Immune response IL-23 signaling pathway 22
Show member pathways
 12.81 TNF IL6 IL2 IL1B IL17A IL10
14
Th17 cell differentiation 36
Show member pathways
 12.81 TNF IL6 IL5 IL4 IL2 IL1B
15
T cell receptor signaling pathway 36
Show member pathways
 12.81 TNF IL6 IL5 IL4 IL2 IL1B
16
NF-KappaB Family Pathway 63
Show member pathways
 12.79 TNF IL6 IL2 IL1B IL1A
17
Immune response NFAT in immune response 22
Show member pathways
 12.77 TNF IL4 IL2 IL10 IFNG CD4
18
4-1BB Pathway 63
Show member pathways
 12.76 TNF IL1B IL1A IFNG CD4
19
NF-kappaB Signaling 4
12.76 TNF IL4 IL2 IL1B IL17A IL10
20
Immune response Role of DAP12 receptors in NK cells 22
Show member pathways
 12.63 TNF IL4 IL2 IFNG ICAM1
21
IL-17 Family Signaling Pathways 64
Show member pathways
 12.6 TNF IL6 IL5 IL4 IL1B IL17A
22
Chemokine Superfamily Pathway: Human/Mouse Ligand-Receptor Interactions 64
Show member pathways
 12.58 TNF IL6 IL2 IL10 CXCR3 CXCL8
23
Folate Metabolism 1
Show member pathways
 12.56 TNF IL6 IL4 IL2 IL1B IFNG
24
JAK-STAT signaling pathway (KEGG) 36
Show member pathways
 12.54 IL6 IL5 IL4 IL2 IL10 IFNG
25
Toll Comparative Pathway 63
Show member pathways
 12.49 TNF IL6 IL1B IL1A IFNG CXCL8
26
Human T-cell leukemia virus 1 infection 36
12.48 TNF IL6 IL2 ICAM1 CD4
27
Toxoplasmosis 36
Show member pathways
 12.46 TNF IL4 IL1B IL1A IL10 IFNG
28
Tuberculosis 36
12.44 TNF IL6 IL1B IL1A IL10 IFNG
29
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.44 TNF IL6 IL5 IL4 IL2 IL1B
30
C-type lectin receptor signaling pathway 36
Show member pathways
 12.42 TNF IL6 IL2 IL1B IL10 CCL17
31
Bacterial infections in CF airways 22
Show member pathways
 12.39 TNF IL6 IL4 IL1B IFNG CXCL8
32
Pathogenic Escherichia coli infection 36
12.38 TNF IL6 IL1B CXCL8
33
IL-1 Family Signaling Pathways 64
Show member pathways
 12.38 TNF IL6 IL1B IL1A CXCL8
34
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
12.38 TNF IL6 IL1B IL1A IL10 CXCL8
35
Diseases associated with the TLR signaling cascade 65
Show member pathways
 12.35 TNF IL6 IL1A CXCL8
36
Th1 Differentiation Pathway 64
Show member pathways
 12.34 TNF IL6 IL2 IL1B IL17A IL10
37
NOD-like receptor signaling pathway 36
12.33 TNF IL6 IL1B CXCL8
38
Necroptosis 36
Show member pathways
 12.31 TNF IL1B IL1A IFNG
39
Fluid shear stress and atherosclerosis 36
12.31 TNF SELE IL1B IL1A IFNG ICAM1
40
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 64
12.26 TNF IL6 IL5 IL4 IL2 IL10
41
Yersinia infection 36
12.24 TNF IL6 IL2 IL1B IL10 CXCL8
42
Microglia Activation During Neuroinflammation: Overview 64
Show member pathways
 12.22 TNF IL6 IL4 IL1B IFNG
43
Spinal Cord Injury 1
12.21 TNF IL6 IL4 IL2 IL1B IL1A
44
AGE-RAGE signaling pathway in diabetic complications 36
12.19 TNF SELE IL6 IL1B IL1A ICAM1
45
Hematopoietic cell lineage 36
12.18 TNF IL6 IL5 IL4 IL1B IL1A
46
Allograft rejection 1 36
Show member pathways
 12.18 TNF IL6 IL5 IL4 IL2 IL1B
47
IL12-mediated signaling events 1
Show member pathways
 12.17 IL4 IL2 IL1B IFNG CD4
48
Interleukin-4 and 13 signaling 65
12.17 TNF IL6 IL4 IL1B IL1A IL17A
49
Osteoclast differentiation 36
12.16 TNF IL1B IL1A IFNG
50
TNF signaling pathway 36
12.16 TNF SELE IL6 IL1B ICAM1
Sources

GO Terms for Contact Dermatitis

About this section

Cellular components related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TNF IL6 IL5 IL4 IL31 IL2
2 membrane raft GO:0045121 9.56 TNF SELE ICAM1 CD4
3 external side of plasma membrane GO:0009897 9.55 TNF IL17A ICAM1 CXCR3 CD4
4 extracellular space GO:0005615 9.53 TNF SELE IL6 IL5 IL4 IL31

Biological processes related to Contact Dermatitis according to GeneCards Suite gene sharing:

(show top 50) (show all 70)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.25 TNF IL6 IL4 IL2 IL1B IL1A
2 positive regulation of transcription, DNA-templated GO:0045893 10.14 TNF IL6 IL5 IL4 IL1B IL10
3 negative regulation of cell proliferation GO:0008285 10.13 IL6 IL1B IL1A IL10 CXCL8
4 positive regulation of gene expression GO:0010628 10.11 TNF IL6 IL4 IL1B IL1A IFNG
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.04 TNF ICAM1 CD4 CCL17
6 leukocyte migration GO:0050900 10.03 TNF SELE IL1B ICAM1
7 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 10.02 TNF IL1B IL1A CD4
8 response to lipopolysaccharide GO:0032496 10.02 SELE IL1B IL10 ICAM1
9 cell-cell signaling GO:0007267 10.02 IL2 IL1B IL17A CCL27 CCL17
10 chemotaxis GO:0006935 10.01 CXCR3 CXCL8 CCL27 CCL17
11 positive regulation of NF-kappaB transcription factor activity GO:0051092 10 TNF IL6 IL1B ICAM1
12 positive regulation of protein phosphorylation GO:0001934 9.97 TNF IL2 IL1B IFNG CD4
13 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.93 IL6 IL5 ICAM1 CD4
14 inflammatory response GO:0006954 9.93 TNF SELE KRT16 IL6 IL5 IL1B
15 neutrophil chemotaxis GO:0030593 9.92 IL1B IL1A CXCL8 CCL17
16 chemokine-mediated signaling pathway GO:0070098 9.91 CXCR3 CXCL8 CCL17
17 regulation of insulin secretion GO:0050796 9.91 TNF IL1B IFNG
18 response to glucocorticoid GO:0051384 9.91 TNF IL6 IL10
19 cellular response to interleukin-1 GO:0071347 9.91 IL17A ICAM1 CXCL8 CCL17
20 humoral immune response GO:0006959 9.9 TNF IL6 IFNG
21 positive regulation of phagocytosis GO:0050766 9.88 TNF IL1B IFNG
22 positive regulation of interferon-gamma production GO:0032729 9.87 TNF IL2 IL1B
23 positive regulation of B cell proliferation GO:0030890 9.86 IL5 IL4 IL2
24 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.86 TNF IL1B IL1A
25 negative regulation of endothelial cell apoptotic process GO:2000352 9.85 IL4 IL10 ICAM1
26 positive regulation of interleukin-6 secretion GO:2000778 9.85 TNF IL1B IL17A
27 positive regulation of interleukin-6 production GO:0032755 9.85 TNF IL6 IL1B IL1A
28 positive regulation of DNA-binding transcription factor activity GO:0051091 9.85 TNF IL6 IL5 IL1B IL10
29 extrinsic apoptotic signaling pathway in absence of ligand GO:0097192 9.84 IL2 IL1B IL1A
30 positive regulation of cytokine secretion GO:0050715 9.84 TNF IL1A IL10
31 positive regulation of vascular endothelial growth factor production GO:0010575 9.83 IL6 IL1B IL1A
32 negative regulation of neurogenesis GO:0050768 9.83 TNF IL6 IL1B
33 positive regulation of osteoclast differentiation GO:0045672 9.8 TNF IL17A IFNG
34 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 TNF IL6 IL4 IL2 IFNG
35 cellular response to lipopolysaccharide GO:0071222 9.8 TNF IL6 IL1B IL1A IL10 ICAM1
36 positive regulation of glial cell proliferation GO:0060252 9.78 TNF IL6 IL1B
37 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 TNF IL1B IFNG ICAM1
38 astrocyte activation GO:0048143 9.77 TNF IL1B IFNG
39 cytokine-mediated signaling pathway GO:0019221 9.77 TNF IL6 IL5 IL4 IL31 IL2
40 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.76 TNF IL1B IFNG
41 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.75 TNF IL1B IL10
42 negative regulation of amyloid-beta clearance GO:1900222 9.74 TNF IFNG
43 positive regulation of isotype switching to IgG isotypes GO:0048304 9.74 IL4 IL2
44 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.74 IL4 IL10
45 negative regulation of lipid storage GO:0010888 9.74 TNF IL6
46 endothelial cell apoptotic process GO:0072577 9.73 TNF IL10
47 regulation of establishment of endothelial barrier GO:1903140 9.73 TNF IL1B
48 positive regulation of interleukin-2 biosynthetic process GO:0045086 9.73 IL1B IL1A CD4
49 positive regulation of JAK-STAT cascade GO:0046427 9.73 TNF IL6 IL5 IL10
50 ectopic germ cell programmed cell death GO:0035234 9.72 IL1B IL1A

Molecular functions related to Contact Dermatitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.13 TNF SELE KRT16 IL6 IL5 IL4
2 cytokine activity GO:0005125 9.44 TNF IL6 IL5 IL4 IL31 IL2
3 chemokine activity GO:0008009 9.43 CXCL8 CCL27 CCL17
4 growth factor activity GO:0008083 9.35 IL6 IL5 IL4 IL2 IL10
Sources

Sources for Contact Dermatitis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....